Chain Drug Review - Application withdrawn
Sanofi-aventis has withdrawn its application to sell rimonabant, an antiobesity drug. The decision came after a Food and Drug Administration panel recommended that the agency not approve the drug because of concerns that its use could lead to depression and suicidal thinking.
Related Results
Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileNew drug application for rimonabant pulledRimonabant enhanced weight loss success, improved lipids
COPYRIGHT 2007 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
